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Background: RNA interference (RNAi) has been used as a promising approach to inhibit human immunodeficiency
virus type 1 (HIV-1) replication for both in vitro and in vivo animal models. However, HIV-1 escape mutants after
RNAi treatment have been reported. Expressing multiple small interfering RNAs (siRNAs) against conserved viral
sequences can serve as a genetic barrier for viral escape, and optimization of the efficiency of this process was the
aim of this study.
Results: An artificial polycistronic transcript driven by a CMV promoter was designed to inhibit HIV-1 replication.
The artificial polycistronic transcript contained two pre-miR-30a backbones and one pre-miR-155 backbone, which
are linked by a sequence derived from antisense RNA sequence targeting the HIV-1 env gene. Our results
demonstrated that this artificial polycistronic transcript simultaneously expresses three anti-HIV siRNAs and
efficiently inhibits HIV-1 replication. In addition, the biosafety of MT-4 cells expressing this polycistronic miRNA
transcript was evaluated, and no apparent impacts on cell proliferation rate, interferon response, and interruption of
native miRNA processing were observed.
Conclusions: The strategy described here to generate an artificial polycistronic transcript to inhibit viral replication
provided an opportunity to select and optimize many factors to yield highly efficient constructs expressing multiple
siRNAs against viral infection.
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RNA interference (RNAi) is a sequence-specific post-
transcriptional gene-silencing mechanism, that was first
discovered in Caenorhabditis elegans [1]. RNAi can be
triggered by small interfering RNAs (siRNAs) or en-
dogenous microRNAs (miRNAs), which are processed
by RNase III-like enzymes [2,3]. Most miRNAs are pro-
cessed from longer primary miRNA transcripts (pri-
miRNA), which are transcribed from genome sequence
by RNA polymerase II promoter [4,5]. Subsequently, pri-
miRNAs are processed into miRNA precursors (pre-
miRNAs) that are approximately 60 nucleotides (nt) long* Correspondence: sxia@xmu.edu.cn
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reproduction in any medium, provided the orby miRNA processing machinery consisting of the nu-
clear Drospha-DGCR8 complex [6,7]. Next, pre-miRNAs
are transported to the cytoplasm by Exportin-5 and fur-
ther processed by Dicer to produce miRNA duplexes of
approximately 22 nt in length [8,9]. The miRNA
duplexes are loaded into the RNA-induced silencing
complex (RISC) to guide RISC-mediated gene regulation
via mRNA cleavage or translational repression [10,11].
Notably, several miRNA genes are encoded as clusters
within the genome sequence and transcribed into pri-
miRNAs simultaneously as clusters[12]. Hence, multiple
miRNAs can be transcribed and processed from a single
transcription unit [13,14].
Regarded as a potent post-transcription gene silencing
tool, RNAi is now used as a standard laboratory tool to
knock down gene expression at the cellular level, as
well as at the organismal level [15,16]. In addition,
RNAi has been successfully used as a promising ap-
proach to inhibit the replication of different viruses,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[17-22]. Many strategies have been proposed to inhibit
HIV-1 replication in cell culture and animal models, in-
cluding siRNA or short hairpin RNA (shRNA) vector-
based or pri-miRNA vector-based approaches [23-25].
These vector-based approaches have demonstrated long-
term inhibition of HIV replication. However, due to the
restriction of the RNAi mechanism (sequence-specificity)
and high mutation rate of HIV-1, escape mutants after
RNAi treatment have been reported [26-28]. Therefore, a
combination of multiple antiviral inhibitors to overcome
escape has been proposed.
Currently, both multiple shRNAs in a combinatorial
vector approach and multiple antiviral siRNAs embedded
in a single polycistronic miRNA transcript approach have
been used to reduce the chance of viral escape [29-32].
Of these approaches, polycistronic miRNA has been
shown to be safer, since the expression of miRNA-like
transcripts is low and regulated, therefore reducing the
risk of toxicity [33].
Native miRNA clusters and tandem copes of miR155
have been employed as the basis for the design of a poly-
cistronic transcript that simultaneously expresses mul-
tiple antiviral siRNAs [29,31,32]. The replacement of the
mature miRNA sequence by the miRNA-like stem will
produce mature siRNAs that specifically target viruses.
Several studies have shown that the native flanking pri-
miRNA sequences and key structural features of the na-
tive miRNAs were retained, as they were thought to be
critical for efficient siRNA processing [31].
In this study, we designed an artificial polycistronic
transcript containing two pre-miR-30a backbones and
one pre-miR-155 backbone, which is driven by a cyto-
megalovirus (CMV) promoter. Moreover, we used anti-
sense RNA sequence targeting the HIV-1 env gene as
the linker to connect the pre-miRNA backbones. This
study demonstrated that the flanking pri-miRNA se-
quence can be replaced and optimized with artificial se-
quence to construct the polycistronic transcript that
expresses three anti-HIV siRNAs simultaneously and effi-
ciently inhibits HIV-1 replication. This strategy provides
a feasible method to replace the flanking pri-miRNA
sequences with other antiviral elements to design more
complicated and efficient inhibitors against pathogens
that are prone to escape.
Results
Screening of shRNA constructs inhibiting HIV-1
replication
To generate highly efficient constructs that inhibit HIV-1
replication, we employed a traditional shRNA-vector
based approach to screen the best siRNA candidates to
inhibit HIV-1 replication. A total of 95 shRNA con-
structs were developed, assisted by online design tools,to specifically target pol and vif transcripts. The pol gene
encodes the key enzyme involved in HIV-1 replication
and vif plays a role in disrupting the antiviral activity of
the human enzyme APOBEC. Among the constructs, 65
shRNA constructs targeted pol and 30 shRNA con-
structs target vif. Each shRNA expression construct was
cotransfected with the pNL4-3 infectious molecular
clone to determine its ability to inhibit virus production.
Fifty-two shRNA constructs with inhibition efficiency
>97% were selected (Figure 1A). The HIV-1 sequence
targeted by these selected shRNA constructs were
aligned with 625 HIV-1 full-length sequences in the Los
Alamos HIV Sequence Database. The three most con-
served siRNA sequences yielded from the shRNA con-
structs (Pol22 (A), Pol25 (B) and Vif1 (C)) were selected
for artificial miRNA transcript construction (Figure 1B).
Construction of single antiviral miRNA transcripts
Selected pol22 (A), pol25 (B) and vif1 (C) siRNAs were
extended from 19 bp to 22 bp by adding the adjacent
sequences of the HIV-1NL4 target sites to the ends. To
generate the artificial miRNA transcripts, the extended
pol22 (A), pol25 (B) and vif1 (C) siRNAs were used to
replace the mature miRNA sequences embedded in the
pre-miR-30a or miR-155 backbones that would be suit-
able for artificial miRNA construction[34,35] (Figure 2A).
The artificial miRNA transcripts were inserted into the
pcDNA3.1 plasmid driven by a CMV promoter.
To determine the inhibitory efficiency, the artificial
miRNA expressing plasmids were cotransfected with
pNL4-3. Artificial miR-LacZ against β-gal-expressing
plasmids was used as negative control, whereas the ori-
ginal shRNA vectors were used as a positive control.
Among the various artificial miRNA constructs screened,
miR-A2, miR-B3, and miR-C1 had the most inhibition
activity against HIV-1 replication (Figure 2B).
Construction of artificial polycistronic miRNA transcripts
In the miR-17-92 cluster, the linker length between two
adjacent stem-loop structures was approximately 130 bp
and the antisense RNA sequences targeted to the HIV-1
may have a lesser side-effect. Therefore, three RNA
sequences 130 bp in length and complementary to the
HIV-1 env sequences, named e1, e2 and e3, were
employed as linker sequences (Figure 3A).
In the constructs, e1, e2 or e3 was added to the down-
stream region of selected miR-A2, miR-C1 or miR-B3,
respectively, for individual miR-A2-e1, miR-C1-e2, and
miR-B3-e3 transcripts. Determination of the inhibitory
activities of these basic structural elements was evalu-
ated by the firefly luciferase reporter assay. Firefly luci-
ferase expression was normalized to the Renilla
luciferase expression from the co-transfected pRL plas-
mid. These three basic constructs were able to inhibit
Figure 1 Screening of highly effective shRNAs against HIV-1 sequences. (A) The relative virus production (black bars) in a cotransfection
assay of indicated shRNAs with HIV-1 infectious clone, pNL4-3. Virus production in the presence of shRNA targeting GFP was used as a negative
control (gray bar). Virus production was measured by CA-p24 ELISA and corrected for transfection efficiency by including Renilla luciferase in the
transfection assay. The ratio between CA-p24 and Renilla values yielded the relative virus production, which was set at 100% for the negative
control. The mean values and standard deviations were obtained from three independent transfections. (B) The 52 shRNA constructs with
inhibition efficiency greater than 97% were aligned with 625 HIV-1 full sequences in the Los Alamos HIV Sequence Database. The non-mutation
percentage of shRNA target sequence is shown here.
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tory efficiency of miR-B3-e3 and miR-A2-e1 decreased
by approximately 50% (Figure 3B).
To investigate whether linkers exerted anti-HIV-1 ac-
tivity, plasmids expressing linkers only were co-
transfected with pNL4-3. Our data demonstrated that
linkers exhibited little antiviral activity (Additional file 1:
Figure S1), which is consistent with the observation that
antisense RNA shorter than 400 nucleotides is incapable
of inhibiting HIV-1 replication[36]. The individual artifi-
cial miRNA transcripts were then ligated to construct
artificial polycistronic miRNA transcripts, which were
named for the miRNA transcript followed by the linker
name. For example, miR-AB stands for polycistronic
miRNA transcript miR-A2-e1 connected by polycistronic
miRNA transcript miR-B3-e3 successively, whereas miR-
BA stands for miR-B3-e3 connected by miR-A2-e1 suc-
cessively (Additional file 1: Figure S2).
Polycistronic miRNA transcripts containing plasmids
were co-transfected with luciferase reporter vectorsinto 293FT cells to measure the gene knockdown effi-
ciency. A single artificial miR-LacZ transcript was used
as negative control. The relative luciferase activity for
the individual polycistronic miRNA transcript was cal-
culated against that of the miR-lacZ transcript. Hence,
the relative luciferase activity of miR-AB was defined
as the miR-AB activity divided by miR-LacZ activity.
The miR-CB construct displayed the highest inhibition
efficiency among the bicistronic miRNA transcripts
(Figure 4A). Next, we constructed two triple cistronic
miRNA transcripts (miR-ACB and miR-CBA) and
tested their suppression activities. Among these, miR-
ACB showed better suppression activity than that for
miR-CBA (Figure 4B). The inhibition efficiency of
miRNA constructs were lower as compared to that
shown by other studies [29,31]. Lo and Stegmeier have
shown that the addition of a gfp gene between the
promoter and the miRNA sequence significantly
increases the inhibition efficiency of the miRNA
[34,37]. Therefore, we attempted a similar technique
Figure 2 Construction of the antiviral miRNA transcripts. (A) The siRNAs A and B were extended and inserted into the miR-30a backbone;
siRNA C was extended and inserted into the miR-155 backbone. Bulges that existed in mature wild-type miRNA were eliminated in antiviral
miRNAs. Extended sequences in 22 bp siRNAs are in lowercase, whereas native mature miRNA sequence or inserted siRNA sequences are boxed.
(B) Screening of effective antiviral miRNAs. The 239FT cells were co-transfected with 500 ng HIV-1 molecular clone pNL4-3, 50 ng pRL, and
100 ng miRNA constructs. The miR-LacZ against β-galactosidase was used as the negative control, whereas shRNAs expressing original 19 bp
siRNA was the positive control. CA-p24 levels in the culture supernatant were measured 2 days post-transfection. CA-p24 expression in the
presence of miR-LacZ was normalized at 100%. Renilla luciferase was used for normalization of transfection efficiency. Error bars represent the
standard deviation of three independent experiments.
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Figure 3 Construction of the basic structural elements. (A) Antisense RNAs targeted to HIV-1 env were used as linkers, and the positions in
the env gene are indicated. (B) Inhibition of the structure elements. Firefly luciferase activity in the cell was measured 2 days post-transfection
and normalized to the Renilla luciferase activity. Firefly luciferase activity in the presence of miR-LacZ was normalized at 100%.
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miRNA constructs.
Construction of MT-4 cells expressing polycistronic
miRNA transcripts
The lentiviral transfer plasmid, pLLKk, contained two
genes encoding enhanced GFP (EGFP) and H-2Kk. ToFigure 4 Screening of the combinations of the basic structural eleme
reporters in 293FT cells. Luciferase activity in cells was measured 48 h post
was used as a negative control. The relative luciferase activity was defined
the combinations of two basic structural elements. (B) Screening of the co
CB with miR-A produces 2 varieties of triple miRNA clusters: miR-ACB and m
miR-CBA.increase the inhibition efficiency, selected antiviral tri-
cistronic miRNA transcripts were inserted into the 3′-
untranslated region (UTR) of the H-2Kk gene. Evaluation
of the inhibitory efficiency of each of the antiviral miR-
NAs embedded in pLLKk was measured using the luci-
ferase reporter system. These data show that miR-ACB
embedded in the pLLKk vector displayed highernts. The miRNA complexes were co-transfected with luciferase
-transfection and normalized to the Renilla luciferase activity. miR-LacZ
according the ratio of individual miRNA to miR-LacZ. (A) Screening of
mbinations of three basic structural elements. The combination of miR-
iR-CBA. The inhibitory effect of miR-ACB was greater than that for
Figure 5 Inhibitory efficiency of miR-ACB in the Lentiviral vector. Inhibitory efficiency of each miRNA element in miR-ACB was measured by
luciferase reporter assays. The miRNA encoding plasmids based on pcDNA3.1 or pLLKK were co-transfected with luciferase reporters and activities
in cells were measured 48 h post-transfection.
Figure 6 Expression levels of mature miRNAs derived from
miR-ACB transcripts compared to individual antiviral miRNA
transcripts. RNA was isolated from MT-4 cell lines expressing
miRNAs and analyzed by northern blot using 19 nt complementary
oligonucleotide probes. U6 RNA served as a loading control.
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expression tests than that embedded in the pcDNA3.1
vector (Figure 5). As expected, the tri-cistronic miRNA
transcript miR-ACB exhibited higher suppression effi-
ciency against the production of HIV-1NL4-3 virus
than any single miRNA transcript (Additional file 1:
Figure S3).
Mature miRNA levels of miR-ACB in MT-4
Recombinant lentiviruses encoding miRNAs transcripts
were used to transduce MT-4 cells. To investigate
whether the significant increase of the inhibition activity
against HIV-1 replication by the artificial tri-cistronic
miRNA transcript was due to the presence of multiple
miRNAs that act synergistically to inhibit HIV-1 repli-
cation, miRNA expression levels in MT-4 cells was
determined by northern blot. As showed in Figure 6,
miR-ACB was successfully processed into three mature
miRNAs and the amounts of these miRNAs were similar
to those from pre-miRNA containing only one antiviral
miRNA.
Evaluation of off-target effects of miR-ACB
As a first step to evaluate the biosafety of MT-4 cells
expressing miR-ACB, three aspects, namely cell prolif-
eration rate, interferon response, and interruption of
native mRNA processing, were assessed in MT-4 cellswith and without miR-ACB transcript expression.
MTT was used to measure the cell proliferation. As
showed in Figure 7A, the expression of the miR-ACB
transcript had no effect on cell proliferation. Similarly,
the protein expression level of Stat1, an interferon-
stimulated transcription activator, was assayed. As
shown in Figure 7B, the expression of miR-ACB tran-
script had no effect on Stat1 expression, which sug-
gests expression of miR-ACB does not trigger the
production of interferon. Finally, there were no altera-
tions in the expression levels of miR-16 and miR-181
accompanying the expression of miR-ACB transcripts
in MT-4 cells (Figure 7C).
Figure 7 Evaluation of off-target effects of miR-ACB. (A) The cell proliferation rate of MT-4 cells with and without miR-ACB. MTT was detected
after cells were plated and cultured 48 h at 37 °C. (B) The Stat1 mRNA level of MT-4 cells with and without miR-ACB was quantified by qPCR and
normalized to the β-actin mRNAs. (C) Expression profiles of miRNAs in MT-4 with and without miR-ACB. Expression level of miRNAs was measured
by qPCR and normalized to that of small non-coding RNA U6B. Error bars in all cases indicate the standard deviation of triplicate cultures.
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To investigate whether miR-ACB has the ability to pre-
vent HIV-1 escape, MT-4 cells expressing miR-A2, miR-
B3, miR-C1 or miR-ACB transcripts were infected with
HIV-1NL4-3. MT-4 cells and MT-4 cells expressing miR-
LacZ transcript were used as negative control. As shown
in Figure 8A, although virus replication was initially
inhibited by miR-A2, miR-B3, and miR-C1, in long term
culture the replication of viruses rebounded. In contrast,
MT-4 expressing miR-ACB transcript was able to inhibit
HIV-1 replication for 21 days. In order to confirm these
results, escaped viruses were collected from the super-
natant of the MT-4 cells expressing single miRNA tran-
script 19 days post-infection and used to re-infect new
MT-4 cells. Resistant virus collected from the miR-A2 cell
supernatant replicated in MT-4 cells, MT-4-miR-LacZ
cells, and MT-4-miR-A2 cells with similar growth kinet-
ics, but were inhibited in the miR-ACB cells (Figure 8B).
Similar results were observed for viruses resistant to
miR-B3 and miR-C1 inhibition (Figures 8C-D). Thus,
miR-ACB showed better inhibitory efficiency than indi-
vidual antiviral miRNA transcripts, and has the potential
to delay the emergence of resistant virus.
Discussion
The selection and construction of cell lines expressing
multiple effective antiviral elements are critical to avoidescape mutations in HIV-1 by RNAi techniques. Expres-
sing multiple shRNAs from separate promoters and long
hairpin RNAs has been reported to achieve inhibition of
viral replication [30,38,39]. However, the high expression
level of RNA polymerase III promoters that are used to
transcribe shRNAs and lhRNAs may increase toxicity
due to saturation of the RNAi machinery [33,40]. An-
other attractive approach is to express multiple antiviral
siRNAs from a single polycistronic miRNA transcript
that can be expressed from a single RNA polymerase II
promoter to allow lower and regulated expression
[29,31]. The native miRNA clusters (mir-17-92 or mir-
106b) were used as the backbone for insertion of mul-
tiple antiviral siRNAs. It was reported that the native
flanking primary miRNA (pri-miRNA) sequences are
maintained to keep the structural features of the native
miRNAs, which are critical for efficient siRNA proces-
sing [31]. In this study, we investigated a method to link
multiple antiviral miRNA against HIV-1 with artificial
flanking pri-miRNA sequence.
Firstly, we employed a conventional antiviral shRNA
approach to select the antiviral small RNA sequences
specifically targeting the two different HIV-1 targets, pol
and vif. Secondly, the three selected small RNA
sequences (pol22, pol25, and vif1 from 95 different
sequences) were modified and ligated into the respect-
ively pre-miR-30a or miR-155 backbones to generate
Figure 8 Inhibition of virus replication in MT-4 cells by miR-ACB. MT-4 cell lines expressing antiviral genes were infected with HIV-1. Viral
replication was monitored by measuring the expression of CA-p24. Values for CA-p24 concentration are averages of three independent experiments.
(A) Wild-type HIV-1NL4-3 virus; (B) miR-A2 resistant virus; (C) miR-B3 resistant virus; (D) miR-C1 resistant virus. MT-4 cells and MT-4-miR-LacZ were used
as negative controls.
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miR-B3 or miR-C1). The individual miRNA transcripts
were linked by arbitrary antisense RNA sequences tar-
geted to HIV-1 env to construct an artificial single cistro-
nic miRNA construct. Finally, the relative positions and
the combinations of these artificial miRNA transcripts,
together with the antisense RNA linker, were optimized
based on a luciferase reporter system to acquire a tri-
cistronic miRNA transcript (miR-ACB) with highexpression levels of three individual antiviral siRNAs
simultaneously. As a result, the MT-4 cells expressing
the selected miR-ACB transcript exerted stronger inhib-
ition of HIV-1 replication than any of the single antiviral
miRNAs and had better suppressive activity against
escaped virus replication than individual miRNA tran-
scripts. Off-target effects of miRNA on cellular tran-
scripts with partial sequence complementarity may
induce negative effects on the treated cell. In this study,
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evaluating cell proliferation rate, interferon response, and
interruption of native mRNAs.
The strategy described here provides a method to con-
struct miRNA polycistrons with artificial flanking pri-
miRNA sequences. The results of this study showed that
the inhibition efficiency of each miRNA embedded in the
tri-cistron construction was lower than that for single
miRNA. However, the opposite was observed for the na-
tive mir-17-92 backbone[29]. These conflicting findings
imply that the miRNA tri-cistron can be further opti-
mized to yield more efficient constructs expressing mul-
tiple siRNAs against viral replication. The factors that
might affect the optimization include the miRNA back-
bones, the combination, and the linkers. Future studies
should investigate the incorporation of other antiviral
elements, such as zinc-finger nucleases, single-chain
antibodies, and ribozymes, into the linker sequence to
produce more antiviral elements from a single miRNA
polycistron to inhibit viral infection/escape.
Conclusions
The tri-cistronic transcript constructed with artificial
flanking pri-miRNA sequences simultaneously expresses
three anti-HIV siRNAs and efficiently inhibits HIV-1 repli-
cation without off-target effects. The strategy described
here provides a feasible method to replace the flanking pri-
miRNA sequences with other antiviral elements to design
more complicated and efficient polycistronic miRNAs.
Methods
Plasmid construction
The shRNA expression plasmids were constructed
according to the pSUPER instructions provided by the
manufacturer (Oligoengine, WA, USA). Target sequences
of shRNAs are shown in the Additional file 1: Table S1.
The pcDNA3.1 vector was mutated to remove BglII site
using QuikChange II Site-Directed Mutagenesis Kits
(Agilent, CA, USA). The miRNA expression plasmids
were constructed by inserting annealed oligonucleotides
(Additional file 1: Table S2), encoding the miRNA target
transcript, into the pcDNA3.1 vector at multiple cloning
sites (BamHI/EcoRI). The basic elements were obtained
by inserting the fragments (EcoRI/XhoI) of the linker
(the 3′ end of each linker contains a BglII cloning sites.)
into the cloning site (EcoRI/XhoI) of the miRNA-
expressing vector. The miRNA cluster was obtained by
inserting the fragment (BamHI/XhoI) of one basic struc-
ture into the cloning site (BglII/XhoI) of pcDNA3.1
expressing upstream basic structures of the cluster.
An H-2Kk expression cassette was cloned from
pMACSKK.II (Miltenyi, Bergisch Gladbach, Germany)
using primers (5′-TTTACTAGTCATGTTTGACAGCT-
TATCATCG-3′and 5′-TTTCTCGAGATACAAGGAT-CCATCTACC CTCCTTTTCCACC-3′). The cleaved
fragment (SpeI/XhoI) was inserted into the cloning site
(XbaI/XhoI) of pLL3.7 to obtain the pLLKk vector.
pCDNA3.1 vectors expressing miRNAs or miRNA clus-
ters were cleaved (BamHI/XhoI) and inserted into the
same cleaved pLLKk. Fragments containing the RNAi tar-
get sequences were generated from pNL4-3 by adding
XbaI at 5′ termination site and FseI at 3′ termination site.
PCR products were cleaved (XbaI/FseI) and inserted into
the cloning site (XbaI/FseI) of the pGL3-control vector
(Promega, Madison, WI) to obtain luciferase reporters.
Cell culture
Human embryonic kidney 293FT adherent cells were
purchase from Invitrogen and grown in Dulbecco’s
modified Eagle’s medium (Invitrogen, Carlsbad, CA)
supplemented with 10% fetal calf serum, penicillin
(100 U/mL) and streptomycin (100 μg/mL). MT-4 and
TZM-bl cells were obtained from the National Institutes
of Health (NIH) AIDS Research and Reference Program
and grown in RPMI 1640 medium (Invitrogen) supple-
mented with 10% fetal calf serum, penicillin (100 U/mL)
and streptomycin (100 μg/mL) (complete medium).
Infectious clone co-transfection experiments
500 ng miRNA expressing vectors (or 500 ng shRNA
expressing vectors), 50 ng pRL Renilla Luciferase Control
Reporter Vectors (Promega) and 100 ng pNL4-3 were
co-transfected into 293FT cells in 24-wells plates at 80%
confluency with Lipofectamine 2000 (Invitrogen, Carls-
bad, CA). At 48 h post-transfection, CA-p24 levels in the
culture supernatant were measured by enzyme-linked
immunosorbent assay (ELISA) 48 h post-transfection.
The cells were lysed with 120 μL Passive Lysis Buffer
(Promega) and luciferase levels were analyzed from
10 μL lysate using the Dual Luciferase reporter assay
(50 μL of substrate reagents; Promega) on a Centro LB
960 Microplate Luminometer (Berthold, Bad Wildbad,
Germany).
Reporter co-transfection experiments
300 ng miRNA expressing vectors, 50 ng pRL, and 300 ng
luciferase reporters were co-transfected into 293FT cells
in 24-well plates with Lipofectamine 2000 (Invitrogen).
Cells were lysed to measure luciferase activity 48 h post-
transfection. Changes in the expression of firefly luciferase
(target) were calculated relative to Renilla luciferase (in-
ternal control) and normalized to levels in cells trans-
fected with the pcDNA3.1 control plasmid expressing
miR-LacZ.
Lentiviral vector production and transduction
The pSUPER-Drosha is a shRNA expressing plasmid
based on pSUPER vector to decrease the level of Drosha
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GUGACUU33). The 293FT cells were seeded in a 10 cm
dish (5 × 106/dish). After 6 h, 12 μg pLLKk-miRNA vec-
tors were co-transfected with 6 μg pVSVG, 6 μg pMDL,
6 μg pREV, and 6 μg pSUPER-Drosha vectors into
293FT cells using Lipofectamine 2000 reagent (Invitro-
gen). Culture medium was replaced 12 h post-
transfection. On the third day of culture, cell culture
supernatant containing lentiviral vectors was harvested
and pooled. Cellular debris was removed by filtration
through a 0.45 μm filter. Lentiviral stocks were titrated
on 293 T cells. MT-4 cells (1 × 105) were transduced with
lentivirus expressing miRNA at a multiplicity of infec-
tion (MOI) of 40. Ten days post-transduction, cells were
sorted with live fluorescence-activated cell sorting
(FACS), and green fluorescent protein (GFP)-positive
cells were selected.
miRNA detection by Northern blotting
Total RNA was isolated using Trizol reagent from
MT-4 cells or MT-4 cells expressing miRNAs. The
miRNAs were detected using a miRNA Northern Blot
Assay Kit (Signosis, Sunnyvale, CA), according to the
manufacturer’s instructions. Biotinylated probes were
used for detection: GTATGTAGGATCTGACTTA
(miR-A), GGATTTACCACACCAGACA (miR-B) and
GTAGACAGGATGAGGATTA (miR-C).
MTT cell viability assay
Cells were seeded at a density of 2000/well in 96-well
plates and grown three days. MTT (Promega) was added
at 15 μL/well and incubated at 37°C for 4 hours. Optical
density was measured at 570 nm. All experiments were
done in triplicate.
miRNA detection by quantitative PCR
Total RNA was isolated using Trizol reagent from MT-4
cells or MT-4 cells expressing miRNAs. The miRNAs
were detected using a Ncode miRNA qRT-PCR Kit
(Invitrogen), according to the manufacturer’s instruc-
tions. Sequences of primers are shown in the Additional
file 1: Table S3.
HIV-1 challenge assays
The titer of HIV-1NL4-3 was determined by infecting
TZM-bl cells and scored for β–galactosidase-positive
cells [41]. Briefly, TZM-bl cells were grown in 96-well
plates at 1 × 104 cells per well. Cells were infected with
50 μL of 10-fold serially diluted virus. Two days post-
infection, cultured cells were fixed and stained. Blue cells
with β-galactosidase activity were counted under a light
microscope. MT-4 cells or MT-4 cells expressing
miRNA were infected by HIV-1 at MOI = 0.1. After 24 h
of infection, cells were washed twice with RPMI 1640medium and cultured in complete medium at 37°C. Viral
spread was monitored by measuring CA-p24 production
by ELISA.
Additional files
Additional file 1: Table S1. shRNA target sequences used in the study.
Table S2. Oligonucleotide primers used for miRNAs construction. Table
S3. Primers used for miRNA detection. Figure S1. Influence of linkers on
the replication activity of HIV-1. For the assays, 300 ng plasmids
expressing linkers, 50 ng pRL, and 300 ng pNL4-3 were co-transfected
into 293FT. Virus production was measured by CA-p24 ELISA and
corrected for transfection efficiency by including Renilla luciferase in the
transfection assay. Signal from cells transfected with EGFP expressing
plasmid was used as the negative control. Figure S2. Structure chart of
artificial miRNAs. Figure S3. Enhanced inhibition efficiency of HIV-1 by
miR-ACB. The miRNA-encoding plasmids based on pLLKk were co-
transfected with pNL4-3 in 293FT cells. Virus production was measured
by CA-p24 ELISA and corrected for transfection efficiency by including
Renilla luciferase in the transfection assay. The signal from the miR-LacZ
transfected cells was used as a negative control.
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